Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARG | Q86W56 | 3/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | PDE4A | P27815 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 3/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | MITF | O75030 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.33 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.32 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4769440 | 1.00 | PARG (0.36) | PARGMAPTPOLBSMN1; SMN2PDE4A | |
| SCHEMBL4769797 | 0.88 | PDE4A (0.37) | MAPTSMN1; SMN2PDE4AMEN1KMT2A | |
| SCHEMBL4769812 | 0.88 | PDE4A (0.37) | MAPTSMN1; SMN2PDE4AMEN1KMT2A | |
| SCHEMBL4763160 | 0.87 | PARG (0.42) | PARGMAPTPOLBSMN1; SMN2PDE4A | |
| SCHEMBL4763164 | 0.87 | PARG (0.42) | PARGMAPTPOLBSMN1; SMN2PDE4A | |
| SCHEMBL4763921 | 0.84 | NPSR1 (0.33) | MAPTPOLBSMN1; SMN2PDE4AALDH1A1 | |
| SCHEMBL4763924 | 0.84 | NPSR1 (0.33) | MAPTPOLBSMN1; SMN2PDE4AALDH1A1 | |
| SCHEMBL4867852 | 0.83 | PARG (0.37) | PARGPDE4ACYP2D6CYP3A4 | |
| SCHEMBL4769025 | 0.83 | C5AR1 (0.37) | — | |
| SCHEMBL4769016 | 0.83 | C5AR1 (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1678181-B1 | A2B ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS INC (US) | 2008-12-31 | — | — | EP | disclosed |